Incyte Completes Acquisition of Escient Pharmaceuticals
Incyte (Nasdaq: INCY) has completed its acquisition of Escient Pharmaceuticals, a clinical-stage company specializing in novel small molecule therapeutics for systemic immune and neuro-immune disorders. This $750 million deal, plus Escient's remaining net cash, enhances Incyte's Inflammation and Autoimmunity (IAI) pipeline. Key assets acquired include EP262, aimed at treating mast cell-mediated diseases, and EP547, targeting cholestatic pruritus. This acquisition underscores Incyte's commitment to innovative therapies for severe inflammatory diseases and leverages Escient’s pioneering work in MRGPR biology.
- Incyte's acquisition of Escient Pharmaceuticals for $750 million enhances its IAI pipeline.
- The addition of first-in-class drugs EP262 and EP547 strengthens Incyte's portfolio.
- EP262 targets chronic inducible urticaria (CIndU), chronic spontaneous urticaria (CSU), and atopic dermatitis (AD).
- EP547 addresses conditions with severe pruritus, including cholestatic pruritus.
- The acquisition demonstrates Incyte's commitment to innovative therapies for severe inflammatory diseases.
- The acquisition cost of $750 million, plus Escient’s net cash, represents a significant financial outlay.
- There's inherent risk and uncertainty in advancing clinical-stage drug candidates through development and regulatory approval.
Insights
Analyzing the acquisition of Escient Pharmaceuticals, the key financial aspect is the cost of the acquisition, which is
From a financial perspective, the acquisition could potentially yield high returns if the clinical development of EP262 and EP547 is successful and these drugs receive regulatory approval. However, investors should consider the inherent risks of investing in clinical-stage acquisitions. The success of these drug candidates is uncertain and delays or failures in clinical trials could negatively impact Incyte's financial performance.
In the short term, this acquisition might exert some pressure on Incyte’s financials due to the upfront cost. Long-term benefits will depend on successful clinical outcomes and subsequent market performance of the new drugs. It's important for investors to track the progress of these clinical trials closely.
The acquisition of Escient Pharmaceuticals brings two promising drug candidates, EP262 and EP547, into Incyte’s pipeline. These candidates are first-in-class and target rare and severe conditions, including mast cell-mediated diseases and cholestatic pruritus.
EP262, targeting MRGPRX2, has potential therapeutic applications in conditions like chronic inducible urticaria and atopic dermatitis. These are areas with significant unmet medical needs and if the drug is effective, it could capture a substantial market.
EP547, which targets MRGPRX4, aims to treat severe pruritus. Severe pruritus, especially in conditions like cholestasis, can significantly affect the quality of life. If successful, this drug would address a critical area that currently has limited treatment options.
For retail investors, understanding the science behind these drugs is key. The novelty and specificity of these drugs mean they address niche markets, which can be very profitable if the drugs are approved. However, the path to approval is fraught with scientific and regulatory challenges.
Acquisition strengthens Incyte’s Inflammation and Autoimmunity (IAI) pipeline and reinforces commitment to bring innovative solutions to patients
"The acquisition of Escient and its first-in-class oral MRGPR antagonists bolsters our Inflammation and Autoimmunity portfolio and our commitment to creating innovative solutions that address the urgent needs of patients living with severe inflammatory diseases," stated Hervé Hoppenot, Chief Executive Officer, Incyte. "We are excited to continue the work started by the Escient team and accelerate the clinical development of these promising therapies."
Through this transaction, Incyte has added EP262 and EP547 to its portfolio. EP262 is a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2). By blocking MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell-mediated diseases including chronic inducible urticaria (CIndU), chronic spontaneous urticaria (CSU) and atopic dermatitis (AD). EP547 is a first-in-class oral MRGPRX4 antagonist with the potential to treat cholestatic pruritus and other conditions with severe pruritus.
“Over the past six years, Escient has pioneered the characterization of MRGPR biology and advanced two novel candidates, EP262 and E547, into clinical development,” commented Joshua Grass, Chief Executive Officer of Escient Pharmaceuticals. "The close of this transaction represents the recognition of value of the innovation by the Escient team, and also represents an exciting transition to Incyte, a global biopharmaceutical company that is well positioned to advance these novel candidates to address the unmet needs of patients worldwide.”
As previously disclosed, under the terms of the agreement, Incyte has acquired Escient and its assets for
Centerview Partners LLC and Goldman Sachs & Co. LLC advised Escient on the transaction, and Fenwick & West LLP acted as legal counsel for Escient. Covington & Burling LLP acted as legal counsel for Incyte.
About EP262
EP262 is a potent, highly selective once-daily small molecule antagonist of MRGPRX2, a receptor expressed on mast cells that is activated by numerous ligands, including many peptides released from sensory neurons as well as other cell types. In response to MRGPRX2 activation, mast cells release histamine, tryptase, chymase, chemokines and cytokines, which can cause itchy hives, angioedema, type 2 inflammation (through engagement of the adaptive immune system) and chronic pruritus and pain. Preclinical data demonstrate that, by blocking activation of MRGPRX2, EP262 has the potential to effectively treat a broad range of mast cell-mediated conditions, with an initial focus on chronic urticarias and atopic dermatitis.
About EP547
EP547 is a potent, highly selective antagonist that blocks the activation of MRGPRX4 by various bile acids, bilirubin and urobilin. By virtue of this disease-specific mechanism of action, EP547 has the potential to be a highly targeted and efficacious treatment for cholestatic and uremic pruritus.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
About Escient Pharmaceuticals
Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders. The company’s pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus. Based in
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the opportunities presented by this transaction; whether and when EP262 or EP547 will be approved for use; whether and when Incyte will bring EP262 or EP547 to market; the potential of EP262 or EP547 to treat patients with atopic dermatitis (AD), chronic inducible urticaria (CIndU) and chronic urticaria (CSU) or for any other indication; and the potential for Incyte to broaden its ability to bring new medicines to patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside of
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530903016/en/
Media
media@incyte.com
Investors
ir@incyte.com
Source: Incyte
FAQ
What did Incyte acquire from Escient Pharmaceuticals?
What are the key drugs included in Incyte's acquisition of Escient?
How does the acquisition of Escient Pharmaceuticals benefit Incyte?
What is EP262 intended to treat?
What condition does EP547 target?
How much did Incyte pay for the acquisition of Escient Pharmaceuticals?
